文献速递胸部肿瘤支持与姑息治疗

参一胶囊联合化疗改善晚期非小细胞肺癌中位生存期的多中心大样本随机临床试验

[A multicenter, large-sample, randomized clinical trial on improving the median survival time of advanced non-small cell lung cancer by combination of Ginseng Rg3 and chemotherapy].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2018-01-01

该多中心、大样本、随机双盲试验纳入414例Ⅲ~Ⅳ期非小细胞肺癌患者,比较标准一线化疗联合参一胶囊与联合安慰剂的疗效。结果显示,治疗组中位生存期12.03个月显著优于对照组8.46个月(P=0.012),且骨髓抑制更轻、KPS及中医证候评分改善更明显。

要点

  • 参一胶囊联合标准化疗可延长晚期NSCLC中位OS至12.03个月,优于安慰剂组的8.46个月。
  • 联合治疗组化疗后血红蛋白和白细胞下降程度显著轻于对照组。
  • 联合治疗组KPS评分及中医证候评分均显著优于对照组。

核心结论

  • 参一胶囊联合化疗的中西医结合疗法可延长晚期非小细胞肺癌患者生存时间并改善症状。

研究设计与样本

  • 多中心、大样本、随机双盲试验,入组Ⅲ~Ⅳ期非小细胞肺癌患者414例,治疗组199例,对照组215例。
  • 治疗组采用标准一线化疗方案联合参一胶囊口服,对照组采用相同化疗方案联合安慰剂治疗。

主要发现

  • 治疗组和对照组中位生存时间分别为12.03和8.46个月,差异有统计学意义(P=0.012)。
  • 化疗第1、2个疗程后两组血红蛋白和白细胞均下降,第2个疗程末治疗组下降水平均小于对照组(均P<0.05)。
  • 化疗第2个疗程末,治疗组和对照组KPS评分分别为(78.95±9.14)分和(76.77±9.15)分,差异有统计学意义(P<0.05)。
  • 化疗第2个疗程末,治疗组和对照组中医证候评分分别为(2.45±1.73)分和(2.92±2.06)分,差异有统计学意义(P<0.05)。

关键数值与推荐

  • 中位OS:治疗组12.03个月 vs 对照组8.46个月,P=0.012。
  • 化疗第2个疗程末KPS评分:治疗组(78.95±9.14)分 vs 对照组(76.77±9.15)分,P<0.05。
  • 化疗第2个疗程末中医证候评分:治疗组(2.45±1.73)分 vs 对照组(2.92±2.06)分,P<0.05。

临床怎么用

  • 对Ⅲ~Ⅳ期非小细胞肺癌患者,标准一线化疗可考虑联合参一胶囊以延长生存并减轻骨髓抑制。
  • 联合治疗可能改善患者体力状态及中医证候,需结合患者具体情况个体化应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To observe the efficacy of the combination of chemotherapy and Ginseng Rg3 on advanced non-small cell lung cancer(NSCLC). Methods: In the multi-center, large-sample, randomized, double blind trial, 414 patients with Ⅲ-Ⅳ NSCLC were enrolled.199 were in the experimental group and 215 the control group. The patients in the experimental group were treated with the standard first-line chemotherapy combined with Ginseng Rg3. The patients in the control group were treated with the same chemotherapy combined with placebo. Median overall survival (OS), Karnofsky performance scale (KPS), Traditional Chinese Medicine (TCM) symptoms score and side effects of two groups were observed as main indexes. Results: The median OS were 12.03 months in the experimental group, which was significantly better than that in the control group (8.46 months, P<0.05). Hemoglobin and white blood cells were decreased after the first and second cycle of treatment in both groups. Both adverse events were significantly milder in the treatment group (P<0.05). In addition, after two courses of treatment, the KPS of patients was 78.95±9.14 in the experimental group and 76.77±9.15 in the control group, while the TCM symptoms score was 2.45±1.73 in the experimental group and 2.92±2.06 in the control group, with significant difference (P<0.05). Conclusions: Combination of TCM with Western medicine such as chemotherapy could prolong the survival of patients with advanced NSCLC. The combined therapy improved patients' symptoms and reduced chemotherapy induced myelosuppression. 目的: 探讨参一胶囊联合化疗对晚期非小细胞肺癌的临床疗效。 方法: 采用多中心、大样本、随机双盲研究方法,入组Ⅲ~Ⅳ期非小细胞肺癌患者414例,其中治疗组199例,对照组215例。治疗组采用标准一线化疗方案联合参一胶囊口服,对照组采用相同的化疗方案联合安慰剂治疗。研究两组患者的中位生存时间、卡氏体力状态(KPS)评分,中医证候评分和不良反应。 结果: 治疗组和对照组患者的中位生存时间分别为12.03和8.46个月,差异有统计学意义(P=0.012)。化疗第1、2个疗程后,两组患者的血红蛋白和白细胞均有下降;化疗第2个疗程末,治疗组血红蛋白及白细胞下降水平均小于对照组,差异均有统计学意义(均P<0.05)。化疗第2个疗程末,治疗组和对照组患者的KPS评分分别为(78.95±9.14)分和(76.77±9.15)分,差异有统计学意义(P<0.05);治疗组和对照组患者的中医证候评分分别为(2.45±1.73)分和(2.92±2.06)分,差异有统计学意义(P<0.05)。 结论: 参一胶囊联合化疗的中西医结合疗法治疗晚期非小细胞肺癌,能够延长患者的生存时间,改善患者的症状,减轻化疗引起的骨髓抑制。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Wang XQ, Liu H, et al. [A multicenter, large-sample, randomized clinical trial on improving the median survival time of advanced non-small cell lung cancer by combination of Ginseng Rg3 and chemotherapy]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29730918. doi:10.3760/cma.j.issn.0253-3766.2018.04.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。